Take a proactive, clinically proven approach to chronic weight management with Saxenda®, a prescription injectable medication designed for adults and adolescents (ages 12–17). Saxenda is indicated for adults with a body mass index (BMI) of 30 or greater (obesity), or 27 or greater (overweight) in the presence of at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
As a glucagon-like peptide-1 (GLP-1) receptor agonist, Saxenda works by mimicking a natural metabolic hormone in your body that regulates appetite. By activating specific areas in the brain responsible for hunger control, it increases feelings of fullness and satisfaction while slowing down stomach emptying. When paired with a reduced-calorie meal plan and increased physical activity, Saxenda helps you achieve and sustain your long-term weight reduction goals.
Key Features & Benefits
-
Targeted Weight Management: Specifically engineered and FDA-approved to support chronic weight management by addressing the biological drivers of hunger.
-
Enhanced Satiety: Works directly with your brain’s natural receptors to help you feel full faster and remain satisfied longer after smaller portions.
-
Daily Dosing Control: Administered once a day at any time, providing consistent, everyday appetite control that adapts flexibly to your daily schedule.
-
All-in-One Multi-Dose Pen: Delivered via a prefilled, adjustable pen injector that makes dialing and tracking your progressive dosing stages straightforward and accurate.
Dosing & Titration Schedule
Saxenda utilizes a progressive five-week titration ladder to allow your digestive system to adapt smoothly. Each prefilled pen contains 18 mg of liraglutide, allowing you to dial the exact dose required for your current week.
| Dosing Phase | Daily Dose | Purpose / Stage | Pen Lifespan (Per Pen) |
| Week 1 | 0.6 mg | Introductory Starting Dose | 30 Days |
| Week 2 | 1.2 mg | Step-Up Dosing Stage | 15 Days |
| Week 3 | 1.8 mg | Intermediate Dosing Stage | 10 Days |
| Week 4 | 2.4 mg | Advanced Dosing Stage | 7.5 Days |
| Week 5 & Onward | 3.0 mg | Full Therapeutic Maintenance Dose | 6 Days |
Administration & Storage Instructions
-
Route: Subcutaneous injection only. Inject once daily into the abdomen, thigh, or upper arm. Rotate your injection site with each daily dose, and never inject into a vein or muscle. Can be taken with or without food.
-
Unopened Pens: Store inside your refrigerator between 36°F–46°F (2°C–8°C) until the printed expiration date. Do not freeze. Do not use if the pen has been frozen.
-
In-Use Pens (Open): Once open, the pen can be kept at room temperature below 86°F (30°C) OR inside the refrigerator for up to 30 days. Keep the pen cap attached when not in use to protect the solution from direct light. Always remove and safely discard the injection needle immediately after every dose.
Important Safety & Prescription Notice: Prescription Required (Rx Only). Saxenda® carries a boxed warning regarding the potential risk of thyroid C-cell tumors. Do not use if you or anyone in your family has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Saxenda contains the same active ingredient as the diabetes medication Victoza and should not be used in combination with it or any other GLP-1 receptor agonist. Common side effects include nausea, diarrhea, constipation, vomiting, low blood sugar, and decreased appetite. Severe but rare risks include pancreatitis, gallbladder disease, and kidney impairment. Dosing plans must be strictly monitored under medical supervision.
Reviews
There are no reviews yet.